Listar por tema "Isoniazid/therapeutic use"

Mostrando ítems 1-2 de 2

Multidrug resistant tuberculosis

Millard, James; Ugarte Gil, Cesar Augusto; Moore, David Alexander James (BMJ Publishing Group, 2015)

Tuberculosis remains a major cause of morbidity and mortality globally, with an estimated nine million people developing the disease and 1.5 million deaths in 2013; equating to 4100 deaths a day.1 Nevertheless, considerable ...
Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin-Mono-Resistant Pulmonary Tuberculosis in Lima, Peru

Villegas, Leonela; Otero Vegas, Larissa; Sterling, Timothy-R.; Huaman, Moises-A.; Van-der-Stuyft, Patrick; Gotuzzo Herencia, José Eduardo; Seas Ramos, Carlos Rafael (Public Library of Science, 2016)

BACKGROUND: Isoniazid and rifampicin are the two most efficacious first-line agents for tuberculosis (TB) treatment. We assessed the prevalence of isoniazid and rifampicin mono-resistance, associated risk factors, and the ...

Buscar en el Repositorio